Phaseline

Targets › OPRD1

OPRD1 (Delta-type opioid receptor): drug programs, companies and trials

17 programs from 17 companies in 64 trials: 25 Phase 2, 16 Phase 4, 12 Phase 1, 11 Phase 3; Psychiatry, Other, Metabolic and endocrine; next expected readout Nov 2026.

G protein-coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. (UniProt, P41143)

Open in Phaseline: the race on OPRD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Zhujiang HospitalAnrikefon
Delta opioid receptor agonist
OPRD1Phase 4Pruritus ChronicDec 2027
Currax PharmaceuticalsNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4ObesityJan 2029
Middle Tennessee Research InstituteNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Low Back Pain–
University of Colorado, DenverNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Harm Reduction–
Friends Research Institute, Inc.Naloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Opioid Use Disorder–
Pouya AzarNaloxone Hydrochloride
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Opioid Use Disorder–
University of Maryland, BaltimoreNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Opioid Use Disorder; PainNov 2026
Adneuris TherapeuticsCebranopadol
Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist
OPRL1, OPRK1, OPRD1, OPRM1Phase 3Pain; Chronic PainJan 2027
Trevi TherapeuticsNalbuphine
Opioid receptors; mu/kappa/delta agonist
OPRK1, OPRD1, OPRM1Phase 3Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute …Aug 2027
AgelessRxNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug …–
AlkermesSamidorphan
Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist
OPRM1, OPRK1, OPRD1Phase 3Schizophrenia–
Medical University of LublinNaltrexone Hydrochloride
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2VulvodyniaDec 2026
New York State Psychiatric InstituteNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2Opioid-use DisorderJan 2027
University of British ColumbiaNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2Opioid-use DisorderDec 2027
ReacX PharmaceuticalsNalmefene
Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist
OPRM1, OPRD1, OPRK1Phase 1Opioid Abuse and Addiction; Behavioural AddictionDec 2026
Akyso TherapeuticsNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 1Opioid Use DisorderOct 2029

Conditions

Alcohol Use Disorder (5) Opioid Use Disorder (5) Opioid-use Disorder (3) Idiopathic Pulmonary Fibrosis (2) Pain (2) Head and Neck Squamous Cell Carcinoma (2) Low Back Pain (1) Refractory Chronic Cough (1) Laryngoscopy (1) Postoperative Pain, Acute (1) Hip Fracture Surgeries (1) Acute Respiratory Distress Syndrome (1)

Modalities

small molecule (14), mixed (2)

Companies

Middle Tennessee Research Institute (1) Trevi Therapeutics (1) Currax Pharmaceuticals (1) New York State Psychiatric Institute (1) University of British Columbia (1) AgelessRx (1) ReacX Pharmaceuticals (1) Akyso Therapeutics (1) University of Maryland, Baltimore (1) Zhujiang Hospital (1) Pouya Azar (1) University of Colorado, Denver (1) Friends Research Institute, Inc. (1) Adneuris Therapeutics (1) Medical University of Lublin (1) University of Pennsylvania (1) Alkermes (1)

Related targets

OPRK1 (16) OPRM1 (16) OPRL1 (1) CHRNA4 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1) CACNB2 (1) CACNB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.